| Literature DB >> 34744442 |
Shaheena Kousar1, Nikhar Rehman1, Asghar Javed2, Aamir Hussain3, Muhammad Naeem1, Samra Masood1, Hafiz Arslan Ali1, Amna Manzoor1, Aleem Ahmed Khan1, Ahmed Akrem1, Fatima Iqbal4, Aqsa Zulfiqar1, Muhammad Bilal Jamshaid1, Muhammad Waqas1, Asma Waseem1, Muhammad Qamar Saeed1.
Abstract
BACKGROUND: The drastic increase in use of antibiotics as a mandatory part of production in poultry and livestock has led to the development of bacterial resistance against antibiotics. The spread of resistant bacteria from poultry to humans increases the risk of treatment failure by antibiotics because of resistance genes transfer. STUDYEntities:
Keywords: MDR; P. aeruginosa; antibiotic resistance; poultry
Year: 2021 PMID: 34744442 PMCID: PMC8565894 DOI: 10.2147/IDR.S324055
Source DB: PubMed Journal: Infect Drug Resist ISSN: 1178-6973 Impact factor: 4.003
Resistance Pattern of P. aeruginosa Isolates Isolated from Around the Farm and Outside the Farm
| Antibiotics | ||
|---|---|---|
| CST | 44 (31.4%) | 36 (22.5%) |
| OFX | 47 (33.5%) | 27 (16.8%) |
| PMB | 65 (46.4%) | 38 (23.7%) |
| TIC | 31 (22.1%) | 14 (8.7%) |
| TZP | 35 (25%) | 20 (12.5%) |
| AMK | 16 (11.4%) | 7 (4.3%) |
| LVX | 51 (36.4%) | 32 (20%) |
| CIP | 26 (18.5%) | 9 (5.6%) |
| FEP | 28 (20%) | 15 (9.4%) |
| MEM | 15 (10.7%) | 8 (5%) |
| GEN | 23 (16.4%) | 11 (6.8%) |
| ATM | 88 (62.8%) | 45 (28.1%) |
| TOB | 4 (2.8%) | 1 (0.6%) |
| IPM | 49 (35%) | 33 (20.6%) |
Abbreviations: CST, colistin; OFX, ofloxacin; PMB, polymyxin; TIC, ticarcillin-clavulanate; TZP, piperacillin-tazobactam; AMK, amikacin; LVX, levofloxacin; CIP, ciprofloxacin; FEP, cefepime; MEM, meropenem; GEN, gentamicin; ATM, aztreonam; TOB, tobramycin; IPM, imipenem.
Comparison of Sensitivity and Resistance Profile, Chi-Square, and P-value of P. aeruginosa
| Number of Sensitive and Resistant Isolates | For Chi-Square Value, No. of | ||||||
|---|---|---|---|---|---|---|---|
| Antibiotics | Pattern | Chi-Square | |||||
| TZP | S | 105 | 140 | 120 | 140 | 22.9 | <0.001 |
| R | 35 | 20 | 40 | 20 | |||
| CST | S | 96 | 124 | 110 | 124 | 7 | 0.005 |
| R | 44 | 36 | 50 | 36 | |||
| MEM | S | 125 | 152 | 143 | 152 | 10.7 | 0.001 |
| R | 15 | 8 | 17 | 8 | |||
| TIC | S | 109 | 146 | 125 | 146 | 34.5 | <0.001 |
| R | 31 | 14 | 35 | 14 | |||
| FEP | S | 112 | 145 | 128 | 145 | 21.3 | <0.001 |
| R | 28 | 15 | 32 | 15 | |||
| PMB | S | 75 | 122 | 86 | 122 | 44.7 | <0.001 |
| R | 65 | 38 | 74 | 38 | |||
| GEN | S | 117 | 149 | 134 | 149 | 22 | <0.001 |
| R | 23 | 11 | 26 | 11 | |||
| CIP | S | 114 | 151 | 130 | 151 | 51.9 | <0.001 |
| R | 26 | 9 | 30 | 9 | |||
Odds Ratio and P-value of ESBL Production and MDR Isolates of P. aeruginosa
| Variables | ESBL Production | Odds Ratio | Multidrug Resistance | Odds Ratio | ||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
| 24 | 116 | 4.5 (1.8–10.8) | 112 | 28 | 13.7 (7.9–24.0) | |
| 7 | 153 | 36 | 124 | |||
Abbreviations: ESBL, extended spectrum β-lactamases; MDR, multidrug resistance.